Nanoparticles Targeting Dendritic Cell Surface Molecules Effectively Block T cell Conjugation and Shift Response by Chittasupho, Chuda et al.
Nanoparticles Targeting Dendritic Cell Surface Molecules 
Effectively Block T cell Conjugation and Shift Response
Chuda Chittasupho1, Laura Shannon2, Teruna J. Siahaan1, Charlotte M. Vines2, and Cory 
Berkland1,3
1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, 66047
2Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical 
Center, Kansas City, KS, 66160
3Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, KS, 
66047
Abstract
Dendritic cells (DCs) are potent professional antigen presenting cells (APC) that activate naïve T 
cells. Interaction of ICAM-1 and LFA-1 molecules on each cell is required for T cell conjugation 
to DCs which leads to naïve CD4+ T cell activation and proliferation. Nanoparticles capable of 
blocking LFA-1/ICAM-1 interaction were studied as inhibitors of T cell conjugation to DCs. 
Primary DCs were primed with ovalbumin, then treated with a peptide that binds ICAM-1 
(LABL), a peptide that binds LFA-1 (cIBR) or the same peptides covalently linked to the surface 
of poly(DL-lactic-co-glycolic acid) nanoparticles (NPs). LABL-NPs and cIBR-NPs rapidly bound 
to DCs and inhibited T cell conjugation to DCs to a greater extent than the free peptides, 
unconjugated nanoparticles (NPs), anti-ICAM-1 antibodies and anti-LFA-1 antibodies. In 
addition, DCs treated with NPs or with cIBR-NPs stimulated the proliferation of T cells, but DCs 
treated with LABL-NPs did not stimulate T cell proliferation. Nanoparticles targeting ICAM-1 or 
LFA-1 also altered cytokine production by DC cocultured with T cells when compared to free 
ligands suggesting these NPs may offer a unique tool for shaping T cell response.
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Professional antigen presenting cells (APC) such as dendritic cells (DCs) help orchestrate 
immune responses to foreign antigens by capturing antigen and loading it onto major 
histocompatibilty complex (MHC) class II. The antigen-primed APC then present the 
antigen to naïve CD4+T cells which express cognate T cell receptors.1 The resulting 
immunological synapse formed between T cells and APCs often initiates signaling events 
for T cell proliferation and effector function such as cytokine production.2 Leukocyte 
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function-associated antigen-1 (LFA-1; primarily on T cells) binding to intercellular adhesion 
molecule 1 (ICAM-1; primarily on DCs) can prolong the immunological synapse and 
support T cell activation.3-5 Targeting of these molecules is known to modify T cell 
activation.6
Molecules that mediate cell adhesion or signaling are typically present in large numbers at 
the cell-cell interface. Several studies have shown that multivalency can enhance the binding 
of ligands to these types of receptors and shift the response of targeted cells.7-10 For 
example, multivalent presentation of anti-CD20 monoclonal antibody fragments can 
enhance the targeting of B cell antigen CD20.10 Similarly, multiple copies of peptide ligands 
on a polymer backbone can improve binding to CD21 on B cells when compared to free 
ligand.11 Arrays of RGD peptides on micelles have been consistently found to dramatically 
enhance binding to αvβ3 receptors in contrast to free RGD peptides.12
The response of cells targeted by multivalent ligands is often unexpected. Antigen valency 
has been found to be a key parameter affecting binding to B cells and cellular response.13 
High valency antigen arrays induced antibody production by B cells, while low valency 
antigen arrays did not.13 Multivalent ligands induced calcium influx in a dose dependent 
manner, whereas the same molar concentration of free ligand did not.13 Ligand valency also 
affects the response of leukocytes undergoing rolling adhesion. For example, multivalent L-
selectin ligands clustered L-selectin and induced L-selectin shedding, but the corresponding 
monovalent ligands did not.14-15 Thus, multivalent ligands can affect cell response in 
addition to enhancing ligand binding.
The binding of LFA-1 and ICAM-1 is also controlled by changes in avidity resulting from 
receptor clustering.16-17 Cell adhesion mediated by ICAM-1 and LFA-1 involves 
multivalent interaction between these two molecules on opposing cells (APC and T cell). 
LABL (ITDGEATDSG) is a peptide modeled after the I domain of LFA-1 which is the 
binding site of ICAM-1. cIBR (cyclo 1,12 Pen-PRGGSVLVTGC) is a cyclic peptide 
derived from domain 1 of ICAM-1 which binds to the I domain of LFA-1.18-19 LABL and 
cIBR peptides inhibit homotypic and heterotypic T cell adhesion as well as mixed 
lymphocyte reactions.20-22
Nanoparticles modified with these peptides (cLABL-NPs and cIBR-NPs) were previously 
used to specifically target ICAM-1 and LFA-1 expressing cells, respectively.23-25 NPs 
targeting these receptors were found to bind cells and rapidly internalize via receptor-
mediated endocytosis. In addition, cIBR-NP blocked the adhesion of T cells to lung 
epithelial cells expressing a high level of ICAM-1.23 Since the oligomeric states of LFA-1 
and ICAM-1 molecules contribute to their ability to regulate T cell responses, it was 
hypothesized that these nanoparticles may bind with high avidity to ICAM-1 or LFA-1 on 
DCs. Such targeted NPs were suspected to be better inhibitors of T cell conjugation to DCs 
compared to free ligands and a potential tool to alter cell response.
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Characterization of nanoparticles and peptide-conjugated nanoparticles
A variety of targeted and control NPs were synthesized. The size of all PLGA NP 
formulations was less than 200 nm and NPs possessed a negative zeta potential (Table 1). 
Low polydispersity values (<0.1) suggested a relatively narrow particle size distribution. 
LABL and cIBR peptides were successfully conjugated to PLGA-NPs. The zeta potential of 
LABL-NPs was more negative than unconjugated NPs, presumably due to the LABL 
peptide having a net charge of −3. cIBR-NPs had a less negative charge than unconjugated 
NPs. Pluronic-COOH groups were probably masked by the cIBR peptide, which has a net 
charge of +1. The amounts of LABL and cIBR peptides attached to NPs were determined by 
quantifying the unconjugated peptide remaining in the medium after the conjugation 
reaction.23 LABL was conjugated with a high density, while cIBR density closely matched a 
previous publication (Table 2).
23 Relative expression of ICAM-1 and LFA-1 on DCs and T cells
Expression levels of ICAM-1 and LFA-1 on activated bone marrow derived dendritic cells 
(DCs) matured with TNF-α and primed with OVA were determined using fluorescent anti-
ICAM-1 and anti-LFA-1. DCs expressed both ICAM-1 and LFA-1 indicating that either 
LABL or cIBR could be used to target these adhesion molecules on DCs (Figure 2A). For 
these studies we used primary CD4+ T cells, which express an ovalbumin specific T cell 
receptor (OT-II). Flow cytometry data showed minimal expression of ICAM-1 on primary 
OT-II T cells but high expression of LFA-1 as expected (Figure 2B). Although NPs were not 
directly incubated with OT II T cells, the relative expression of these two receptors was 
provided for reference.
Both LABL-NPs and cIBR-NPs exhibited rapid binding to DCs
LABL peptide binds specifically to the domain 1 of ICAM-1, whereas cIBR peptide binds 
the I domain of LFA-1.18-19 LABL-NPs, cIBR-NPs and unconjugated NPs were incubated 
with DCs to investigate the binding by DCs. Immature DCs were stimulated with TNF-α 
and primed with OVA for 24 hrs prior to addition of NPs. In comparison to untargeted NPs, 
fluorescent intensities of DCs incubated with LABL-NPs or cIBR-NPs were much higher 
than cells incubated with untargeted NPs at all incubation times. Fluorescence intensities of 
DCs incubated 45 minutes with LABL-NPs or cIBR-NPs were ~2 and ~2.3 fold greater than 
NPs, respectively, indicating that the interactions of LABL-NPs and cIBR-NPs with DCs 
occurred more rapidly and to a greater extent compared to untargeted NPs (Figure 3).
Fluorescence microscopy of DCs binding nanoparticles
The binding of NPs, LABL-NPs or cIBR-NPs by DCs was also followed using fluorescence 
microscopy. Nanoparticle fluorescence rapidly localized to DCs (Figure 4A). Images 
collected using MetaMorph were analyzed using ImageJ software and showed ~2 times 
greater fluorescence intensity of DCs incubated with LABL-NPs compared to untargeted 
NPs at 40 min (Figure 4B), thus supporting flow cytometry results. DCs treated with cIBR-
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NPs demonstrated even higher fluorescent intensities. These results indicated that LABL-
NPs and cIBR-NPs effectively targeted DCs.
The internalization of LABL-NPs and cIBR-NPs was supported by the punctate 
fluorescence pattern observed in the micrographs. Similar patterns were also reported for the 
uptake of untargeted NPs and cLABL-NPs in lung epithelial cells (A549 cells) and 
endothelial cells (HUVECs) expressing high levels of ICAM-1 in previous reports.24-25 The 
punctate pattern of cIBR-NPs appeared slightly more evident than LABL-NPs and 
untargeted NPs at 40 min of incubation (Figure 4A). These results supported the flow 
cytometry data.
In vitro cellular cytotoxicity of LABL-NPs or cIBR-NPs
Cell viability studies indicated that LABL-NPs and cIBR-NPs were minimally cytotoxic to 
DCs and T cells. The average cell viability was greater than 95% at all concentrations tested 
when LABL-NPs and cIBR-NPs were incubated with DCs for 24 hrs (Figure 5A and 5B). 
For reference, the viability of T cells exposed to LABL-NPs and cIBR-NPs relative to 
untreated cells was also evaluated. After 24 hrs of treatment, a decrease in T cell viability 
was observed at LABL-NPs concentrations higher than 16 mg/ml (IC50 = 25.6 mg/ml). The 
IC50 of cIBR-NPs with T cells was 3.4 mg/ml. From our results, we inferred that DCs were 
highly viable after incubation with these particles for 30 min in the conjugation study. DC 
cultures were washed to remove any free NPs prior to addition of primary T cells; therefore, 
T cell cytotoxicity data is only offered for references.
Peptide-NPs significantly inhibited the conjugation of DCs and T cells
The induction of cell proliferation and cytokine production in resting T cells requires 
binding of LFA-1 on T cells and its receptor, ICAM-1 on DCs to allow prolonged 
signaling.3-5 The effect of LFA-1/ICAM-1 blockade on conjugate formation between T cells 
isolated from B6.129S7-Rag1tm1Mom Tg(TcraTcrb)425Cbn mice and mature DCs primed 
with OVA was investigated. LABL-NP blockade of ICAM-1 on DCs led to a substantial 
decrease in the number of T cells bound to DCs (Figure 6). Pretreatment of DCs with 
LABL-NPs resulted in up to a 76% decrease in T cell binding to DCs compared to T cells 
incubated with untreated DCs. From these results, we inferred that LABL-NPs bound 
ICAM-1 expressed on DCs and blocked the availability of ICAM-1 to interact with LFA-1 
on T cells. The number of T cells interacting with DCs pretreated with cIBR-NPs was 
decreased up to 78% compared to T cells incubated with untreated DCs. Untargeted NPs 
decreased the T cell conjugation to DCs by only 23%.
In addition, free peptides were incubated at molar concentrations corresponding to the molar 
amount of peptides presented on the surface of nanoparticles. Peptide-conjugated 
nanoparticles blocked the binding of T cells to DCs significantly better than free peptides. 
Furthermore, inhibition of the T cell conjugation to DCs was further enhanced by increasing 
LABL-NP or cIBR-NP concentration. These data were also analyzed by counting T cells 
conjugated to DCs (supplementary Figure 1) and the results were in agreement with the 
analysis reported here using Image J software.
Chittasupho et al. Page 4






















Effects of LABL-NPs and cIBR-NPs on T cell proliferation
To examine the effect of NPs on T cell proliferation, carboxyfluorescein diacetate 
succimidyl ester (CFSE) fluorescence dilution in OVA-specific T cells was analyzed after 
co-incubation with DCs for 24 hrs (1 day) and 168 hrs (7 days). DCs were pretreated with 
untargeted nanoparticles (NPs), antibodies, free peptides or peptide-conjugated NPs. The 
three different molar concentrations of free peptides matched the molar concentration of 
peptide conjugated to NPs. Division of cells was calculated from the percentage of cells 
having diluted fluorescent intensity using Flowjo software. Untargeted NPs and cIBR-NPs 
incubated with DCs led to a substantial increase in the number of T cells undergoing 
division. We observed that 89%, 78% and 41% of T cells divided following co-incubation 
with DCs which had been pretreated with NPs (2.2 mg/ml) or cIBR-NPs (4.4 and 2.2 
mg/ml) for 7 days, respectively. In contrast, T cells incubated with untreated DCs only 
proliferated ~6%.
The proliferation of T cells incubated with DCs pretreated with anti-ICAM-1, anti-LFA-1, 
LABL peptide, LABL-NPs (4.4, 2.2 and 1.1 mg/ml) or cIBR peptide were not substantially 
altered by the treatments (Figure 7). There were no significant differences in the levels of T 
cell proliferation between the groups of DCs treated with these samples when compared to 
untreated DCs. T cells alone without DCs were used as a negative control and yielded a T 
cell proliferation of only ~1.8%.
Cytokine production of DCs and OT-II T cells
One marker for DC maturation and T cell stimulation is the production of cytokines. 
Cytokines are produced by both antigen presenting cells such as DCs and by T cells. DCs 
predominantly produce TNF-α, IL-1 and IL-6.26 IL-2 is produced by CD4+ T cells.27 To 
observe cytokine production of DCs after treatment with peptides or nanoparticles, DCs 
matured with TNF-α and primed with OVA were incubated with LABL peptide, cIBR 
peptide, LABL-NPs, cIBR-NPs, or NPs for 30 min. DC cultures were washed and then OT-
II T cells were cocultured with DCs for 7 days and cytokine production was determined by 
enzyme-linked immunoassay (ELISA). DCs incubated with LABL-NPs, cIBR-NPs or NPs 
secreted significantly higher amounts of TNF-α (4-5 fold), relative to untreated DCs. In 
contrast, the amounts of TNF-α produced by DCs treated with LABL and cIBR peptide 
solutions were very low similar to untreated DCs (Figure 8A).
Furthermore, the amount of IL-6 produced by coculture of T cells with DCs pretreated with 
untargeted NPs was not significantly different from the coculture of untreated DCs and T 
cells. Conversely, the amount of IL-6 produced by coculture of T cells with DCs pretreated 
with LABL peptide, cIBR peptide, LABL-NPs or cIBR-NPs were lower than coculture of 
untreated DCs and T cells (Figure 8B). These results suggested that LABL peptide, cIBR 
peptide, LABL NPs and cIBR-NPs, did not stimulate IL-6 production, which is 
predominantly produced by DCs.26 Untargeted NPs did not alter IL-6 production relative to 
untreated DCs suggesting that these particles neither bound specifically to cell adhesion 
molecules nor blocked the activation of the OTII T cells.
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Proliferation of naïve CD4+ T cells into effector T cells is also regulated by mature DCs. 
Coculture of OT-II T cells with DCs that had been pre-incubated with untargeted NPs 
enhanced T cell proliferation and production of IL-17, when compared to other treatments or 
controls (Figure 8C). From these results we concluded the presence of untargeted NPs 
promotes activation of T cells and may increase production of TGFβ, which is normally 
considered immunosuppressive. Yet, in the presence of IL-6, TGF-β promotes the 
expression of IL-17 and the differentiation of Th17 CD4 cells.28 These findings are further 
supported by the low levels of IL-6 produced by LABL, cIBR, LABL-NPs and cIBR-NPs 
treatments which correlate with the production of IL-17 since IL-6 in combination with 
TGF-β induces Th17 differentiation from naïve CD4+ T cells.28 Finally, the amount of IL-2 
was undetectable in all media of DCs cocultured with OT-II T cells.
Discussion
A critical step in the development of an immune response is the activation of T cells. This 
process transitions naïve CD4+ T cells into effector cells. T cell activation begins with 
antigen recognition through a highly specific interaction between T cell receptor (TCR) and 
antigenic peptide presented by major histocompatibility complex (MHC) molecules on the 
surface of antigen presenting cells.1 The activation of a T cell by an APC requires the 
reorganization of receptors and ligands to form an immunological synapse. This dynamic 
and highly organized structure maintains the cell-cell interaction.29 The immunological 
synapse is formed by a re-arrangement of receptors that form supramolecular activation 
clusters. The central cluster is comprised of TCR-peptide-MHC interaction which is 
surrounded by LFA-1 and ICAM-1 adhesion molecules, among others, in the mature 
immunological synapse.30 The binding of TCRs to peptide-MHC complexes further 
activates LFA-1 on T cells that recognize and bind ICAM-1 on APC.2 This interaction 
strengthens the conjugation of APC and T cells and completes the immunological synapse 
which can lead to efficient T cell activation.29-30
ICAM-1 belongs to the immunoglobulin superfamily and is expressed constitutively at low 
levels on APC, endothelial cells, and other cell types.16 The upregulation of ICAM-1 can be 
induced by inflammatory mediators such as IL-1.31 Generally, the binding of cell adhesion 
molecules is enhanced by oligomerization and clustering of the adhesion molecules.16 
ICAM-1 rearranges into non-covalent homodimers on the cell surface via interactions 
between domain 4 (D4).16 Moreover, D4-D4 dimers can then be non-covalently linked by 
interaction of domain 1, resulting in a “W” shaped tetramer that forms linear arrays that are 
likely bent into circular arrays. This organization of ICAM-1 influences formation of the 
immunological synapse (Figure 1).16
The binding of LFA-1 to ICAM-1 is also tightly regulated. The interaction of LFA-1 to 
ICAM-1 is driven by cluster formation and a change in LFA-1 conformation leading to 
higher avidity and affinity, respectively.17 Binding of TCRs to peptide-MHC complexes 
generates intracellular signals leading to an increase in avidity of LFA-1 binding by forming 
a cluster.17, 32 The adhesion of DCs and T cells involves LFA-1 and ICAM-1 clusters, made 
up of thousands of molecules.16 The high densities of ICAM-1 on APCs and LFA-1 on T 
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cells are necessary for firm, long-lasting conjugation. Thus, the nature of T cell conjugation 
to DCs suggests that multivalent inhibitors may pose an interesting intervention.
LABL and cIBR peptides have been shown to bind specifically to ICAM-1 and LFA-1, 
respectively.19-20 These peptides also specifically bind their respective ICAM-1 and LFA-1 
receptors when conjugated to nanoparticles.23, 25 Presenting these as multivalent arrays on 
the nanoparticle surface was hypothesized to provide more potent intervention strategies due 
to enhanced binding avidity, triggered endocytosis of receptors, and changes in cell response 
(Figure 1).33-34
In this study, pretreatment of DCs with LABL-NPs yielded up to a ~76% decrease in T cell 
conjugate formation with DCs suggesting that LABL-NPs bound to ICAM-1 on DCs and 
blocked the availability of ICAM-1 to interact with LFA-1 on T cells. Similar results were 
obtained when DCs were pre-treated with cIBR-NPs. The quantity of T cells binding to DCs 
treated with cIBR-NPs was reduced by 78% when compared to untreated control. LABL-
NPs and cIBR-NPs blocked T cell conjugation to DCs to a greater extent than LABL 
peptide, cIBR peptide, anti-ICAM-1 antibody, anti-LFA-1 antibody and unconjugated NPs.
Inhibition of T cell conjugation to DCs was most likely due to an increase in the binding 
avidity of multivalent peptides and perhaps internalization of cell adhesion molecules 
facilitated by the nanoparticles.33-34 Multiple copies of LABL or cIBR peptide conjugated to 
the surface of nanoparticles were hypothesized to induce the clustering of LFA-1 and 
ICAM-1, hence enhancing the binding avidity of peptides to activated, high-density 
receptors. Welder et al has shown that monovalent soluble ICAM-1 is unable to bind 
efficiently to LFA-1 expressing cells unless it is rendered multivalent by coupling to 
polystyrene microspheres.34 Furthermore, the peptide-NPs were suspected to sustain 
inhibition by inducing receptor internalization. Internalization of clustered ICAM-1 on 
endothelial cells is known to be triggered by multimeric anti-ICAM-1 conjugated on 
microspheres, whereas monomeric anti-ICAM-1 was not efficiently internalized.33 LABL-
NPs and cIBR-NPs have also been shown to be internalized into lung epithelial cells and 
HUVEC cells expressing ICAM-1 and T cells expressing LFA-1, respectively.23-25 Here, 
the punctate staining patterns observed in DCs treated with NPs indicated uptake, and 
presumably receptor internalization.
LABL-NPs, cIBR-NPs, and NPs induced TNF-α production which may result from 
endocytosis or processing of particles in DCs.35 Indeed, PLGA nanoparticles have been 
shown to induce proinflammatory cytokine production and increase T cell proliferation.36-38 
Co-incubation of T cells with DC that had been pretreated with untargeted NPs led to high 
levels of TNF-α, IL-6 and IL-17 and augmented T cell proliferation relative to untreated 
DCs. A similar observation was previously reported in DCs treated with PLGA 
microspheres.39 LABL-NPs decreased the production of IL-6 from DCs and/or OT-II T cells 
and also resulted in a decrease the amount of IL-17, presumably by inhibiting T cell 
differentiation into Th17 cells.
DCs pretreated with cIBR-NPs also induced TNF-α production and proliferation of OT-II T 
cells in a dose dependent manner. Significantly lower levels of IL-6 and IL-17 were 
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produced when comparing cIBR-NPs to other NPs or to untreated coculture. In addition, it 
was unclear whether the T cells that proliferate following stimulation of T cells with cIBR-
NP treated DC were Th1, Th2 or Th17 cells. Based on previous reports, LFA-1 does not 
seem to deliver a costimulatory signal but improves engagement of TCR by promoting 
adhesion of T cells to APC.3 Blockade of LFA-1 on DCs would, therefore, not be expected 
to inhibit T cell activation by DCs. However it could change the T cell differentiation by 
changing the microenvironment of T cell during activation. Although cIBR-NPs blocked T 
cell conjugation to DCs initially, this effect was most likely transient, since substantial T cell 
proliferation was observed at day 7. Data also showed that increasing cIBR-NP dose 
ultimately increased T cell proliferation.
Conclusion
Chemical conjugation of LABL and cIBR peptides to PLGA NPs generated efficient 
targeting to ICAM-1 and LFA-1 receptors on DCs, respectively. LABL-NPs and cIBR-NPs 
were found to be effective inhibitors of T cell conjugation to DCs. LABL-NPs and cIBR-
NPs blocked T cell conjugation to DCs more efficiently than untargeted NPs, free peptides 
and antibodies. Compared to controls, T cell proliferation was arrested when T cells were 
incubated in the presence of DCs treated with LABL-NPs, whereas DCs treated with cIBR-
NPs or untargeted NPs dramatically stimulated the division of T cells. These findings 
suggested the potential of LABL-NPs to change the character of mature DCs, yet block 
immunological synapse formation without stimulating T cell proliferation and point to 
cIBR-NPs as inducers of T cell expansion. All NPs increased the production of TNF-α 
compared to free ligands or untreated controls, but the amount of IL-6 or IL-7 depended on 
NP type. Collectively, results suggested that LABL-NPs and cIBR-NPs function as distinct 




LABL peptide (ITDGEATDSG, Mw 964.95) and cIBR peptide (cyclo 1,12 Pen-
PRGGSVLVTGC, Mw 1174.50) were synthesized on a Pioneer peptide synthesizer 
(PerSeptive Biosystems, CA). Poly(DL-lactic-co-glycolic acid) (50:50) with terminal 
carboxyl group (PLGA, inherent viscosity 0.67dL/g, Mw ~90 kDa) was purchased from 
Lakeshore Biomaterials (Birmingham, AL, USA). Pluronic®F-127 was obtained from 
BASF Corporation. (Mount Olive, NJ, USA). 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC), N-hydroxysulfosuccinimide 
(sulfo-NHS) and 2-β mercaptoethanol were purchased from Thermo Fisher Scientific Inc. 
(Rockford, IL, USA). Coumarin-6 was purchased from Polysciences, Inc. (Warrington, PA, 
USA). Dialysis membrane (MwCO 100,000) was purchased from Spectrum laboratory 
Products Inc. (Rancho Dominguez, CA, USA). RPMI-1640 medium was obtained from 
Cellgro (Manassas, VA, USA). Tumor Necrosis Factor-α (TNF-α) was purchased from 
Promega (Madison, WI, USA). Granulocyte Macrophage-Colony Stimulating Factor (GM-
CSF) was purchased from Peprotech Inc. (Rocky Hill, NJ, USA). Carboxyfluorescein 
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diacetate succimidyl ester (CFSE) and 5-(and-6)-(((4cloromethyl) 
enzoyl)amino)tetramethylrhodamine (Orange CMTMR) were purchased from Invitrogen 
Corporation, (Carlsbad, CA). Monoclonal anti-human CD54 (ICAM-1) Domain 1 and 
Monoclonal anti-LFA-1 were purchased from Ancell (Bayport, MN, USA). CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation Assay (MTS) was purchased from Promega 
(Madison, WI, USA). Ovalbumin was purchased from Sigma (St. Louis, MO). Penicillin, 
streptomycin and L-glutamine were purchased from Cellgro (Manassas, VA, USA). IL-2 
was generously provided by Dr. Christophe Nicot at the University of Kansas Medical 
Center. B6.129S7-Rag1tm1MomTg(TcraTcrb)425Cbn mice were purchased from Taconic 
Farms (Hudson, NY). C57BL/6 wildtype mice were purchased from Jax labs (Bar Harbor, 
ME).
Methods
Cell culture and isolation
Bone marrow derived dendritic cells were generated from C57BL/6 wildtype mice as 
described.40 Briefly, 2 × 106 cells were isolated from bone marrow, plated on bacterial Petri 
dishes and cultured in 10 ml DC media (RPMI-1640, 10% heat inactivated fetal bovine 
serum, 100 μg/ml penicillin-streptomycin, 50 μM β-mercaptoethanol, 20 ng/ml murine 
granulocyte macrophage colony stimulating factor (GM-CSF) (R&D), and 2 nM L-
glutamine. At 72 hours (Day 3), 10 ml of fresh DC media was added to each dish. On days 6 
and 8, 10 ml of supernatant and cells were removed, cells recovered by centrifugation (90 × 
g) and added back to the dish with fresh DC medium. On day 9 non-adherent cells were 
collected, labeled with (5 μM) 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester 
(CFSE) for 10 minutes at 37°C, washed, primed with 50 μg/ml ovalbumin, and matured 
overnight with 100 ng/ml TNF-α.
On day 10, T cells were isolated from B6.129S7-Rag1tm1Mom Tg(TcraTcrb)425Cbn mice 
spleens by passing spleens through a wire mesh. T cells were purified using a negative 
selection, mouse T cell enrichment kit according to manufacturers’ directions (EasySep).
PLGA nanoparticle preparation and characterization
PLGA nanoparticles and nanoparticles loaded with coumarin-6 were prepared by a solvent 
displacement method. In brief, PLGA was dissolved in acetone (18 mg/ml) containing 
coumarin-6 (50 μg/ml). The solution was gently infused into 0.1% Pluronic®F-127-COOH 
(25 ml) under mild stirring (300 RPM). Terminal hydroxyl groups on Pluronic®F-127 were 
converted to carboxyl groups according to a reported procedure.25, 41 The resultant 
nanoparticle suspension was dialyzed (100,000 MWCO) against a 0.2% mannitol solution 
for 48 hrs to remove excess surfactant. Particle size and zeta potential of nanoparticles were 
characterized using dynamic light scattering (ZetaPALS, Brookhaven instrument Inc.).
Conjugation of LABL and cIBR peptides to PLGA-nanoparticles
The N-terminus of peptide was covalently linked with the carboxyl groups of 
Pluronic®F-127-COOH coated on PLGA nanoparticles by carbodiimide chemistry.23 
Specific binding of the LABL and cIBR peptides suggests they are radially pointing away 
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from the particles surface (Figure 1). Nanoparticles (2.2 mg/ml) were buffered using 2-(N-
morpholino)ethanesulfonic acid (MES; pH 6.5) and incubated with 100 mM 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC) and 50 mM N-
hydroxysulfosuccinimide (sulfo-NHS) for 15 min. EDC was used to react with a carboxyl 
group on PLGA NPs and formed an amine-reactive O-acylisourea intermediate. Sulfo-NHS 
was added to stabilize this intermediate, hence increasing the efficiency of coupling 
reaction. Excess EDC and sulfo-NHS were removed by centrifugation (16,089 g, 10 min). 
Then, cIBR or LABL peptides (0.4 mg) were added and allowed to react with 
Pluronic®F-127-COOH on nanoparticles for 12 hrs at room temperature. Peptide conjugated 
NPs were collected by centrifugation (16,089 g, 10 min) and washed three times with 
purified water.
The conjugation efficiency was determined by quantifying the unconjugated ligand 
remaining in the reaction medium after nanoparticle separation. The peptide density on the 
surface of nanoparticles after reaction was calculated assuming a normal Guassian particle 
size distribution.23, 25 The amount of free peptides in reaction medium was analyzed by 
gradient reversed phase HPLC (SHIMADZU) using a C18 column. The HPLC consisted of 
SCL-10A SHIMADZU system controller, LC-10AT VP SHIMADZU liquid 
chromatograph, SIL-10A XL SHIMADZU autoinjecter set at 30 μl injection volume, 
DGU-14A SHIMADZU degasser, sample cooler, and SPD-10A SHIMADZU UV-Vis 
detector (220 nm). The HPLC-UV system was controlled by a personal computer equipped 
with SHIMADZU class VP Software. All separations were carried out using a Vydac® 
HPLC Protein and Peptide C18 column. Gradient elution was carried out to determine the 
amount of LABL peptide at constant flow of 1 ml/min, from 0% B to 8% B for 5 min, 
followed by 14.3% B at 17.5 min, 50% at 23 min and 70% B at 24-35 min. HPLC gradient 
system was programmed to separate cIBR peptide at constant flow of 1 ml/min, from 25% B 
for 5 min, 55% B at 25 min and 100%B at 25.1-30 min. Mobile phase compositions were 
(A) acetronitrile-water (5:95) with 0.1% TFA and (B) 100% acetonitrile with 0.1% 
trifluoroacetic acid (TFA).
LFA-1 and ICAM-1 expression on dendritic cells and T cells
The relative expression of LFA-1 and ICAM-1 on T cells and DCs were qualitatively 
assessed using flow cytometry (FACScan). DCs (4 × 105 cells/ml) were matured with TNF-
α (1,000 U/ml) and primed with ovalbumin (OVA) (50 μg/ml) for 24 hrs. DCs were isolated 
by centrifugation, and incubated 45 minutes on ice with 80 μl of anti-ICAM-1 (0.05 mg/ml) 
or anti-LFA-1 (0.25 mg/ml) conjugated with FITC at 1:50 dilution. Cells were washed three 
times and analyzed by flow cytometry.
Splenic C57BL/6-TgN(OT-II.2a)-Rag1 T cells (2.2 × 106 cells/ml) were incubated with 80 
μl of anti-ICAM-1-FITC (0.05 mg/ml) or anti-LFA-1-FITC (0.25 mg/ml) on ice for 45 min. 
Unbound antibodies were removed by rinsing three times with PBS after centrifugation 
(16,089 g, 2.5 min). The fluorescent intensity of cells was measured by a FACscan flow 
cytometer. Data analysis was performed using Cell Quest software (BD).
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Binding and uptake of LABL-NPs and cIBR-NPs into DCs
The binding and uptake of LABL-NPs and cIBR-NPs encapsulated fluorescent dye was 
monitored using flow cytometry. DCs (1 × 105 cells/ml) were added and allowed to adhere 
on a 96 well-plate (200 μl/well) for 24 hr in the presence of TNF-α (1,000 U/ml) and OVA 
(50 μg/ml). DCs were washed three times with PBS and incubated with NPs, LABL-NPs or 
cIBR-NPs (2.2 mg/ml, 100 μl) at 37 °C for 15, 30, 45 and 60 min. Cells were washed three 
times with PBS and trypsinized for 3 min at 37°C. Then DCs were transferred to 
microcentrifuge tube and washed once with PBS by centrifugation (600 g, 2 min). The 
fluorescent intensity due to DC uptake of fluorescent NPs was measured using the FACscan 
flow cytometer. Data analysis was performed using Cell Quest software (BD).
Fluorescence microscopy of DCs binding/uptake with LABL-NPs or cIBR-NPs
Dendritic cells (1 × 106 cells/ml, 300 μl) were added into an 8-well plate and stimulated by 
TNF-α (1,000 U/ml) and OVA (50 μg/ml) for 24 hrs. Cells were washed with PBS and then 
incubated with NPs, LABL-NPs or cIBR-NPs (2.2 mg/ml, 300 μl) for 40 min at 37°C. 
Unbound nanoparticles were removed by washing three times with PBS and cells were fixed 
with 4% paraformaldehyde. Fluorescence micrographs were acquired using the FITC filter 
set of a Nikon Eclipse 80i microscope equipped for epifluorescence. Micrographs were 
captured using an Orca ER camera (Hamamatsu, Inc., Bridgewater, NJ) and analyzed by 
Metamorph, version 6.2 (Universal Imaging Corp., West Chester, PA). All images were 
corrected for variations in excitation light intensity.
In vitro cellular cytotoxicity of LABL-NPs and cIBR-NPs
MTS cell viability assays were performed to provide an assessment of the toxicity of LABL-
NPs and cIBR-NPs on T cells and TNF-α stimulated and OVA primed DCs. Briefly, T cells 
(3.2 × 106 cells/ml) and DCs (1 × 105 cells/ml) were seeded on 96-well plates and incubated 
with various concentrations of LABL-NPs and cIBR-NPs for 24 hr. A tetrazolium salt MTS 
was applied and the incubation was continued for additional 4 hrs. MTS was converted by 
mitocondrial dehydrogenase enzyme in living cells to form a colored formazan product. The 
absorbance of the formazan product was recorded at 490 nm using a 96-well plate reader 
(Spectramax M5).
DCs and T cell conjugate formation
DCs (4 × 105 cells/ml) were stained by incubating with 5 ml of CFSE in PBS (10 μM) for 10 
min at 37 °C in PBS. The staining was quenched by the addition of 25 ml of complete 
culture medium and incubation at 4°C for 10 min. The remaining dye was washed away by 
three washes with complete culture medium. T cells were incubated with 10 μl of CMTMR 
orange fluorescent dye (5 μM) in 10 ml of PBS for 30 min at 37°C. The reaction of the dye 
was quenched by incubating with complete culture medium for 30 min at 37°C. T cells were 
washed three times with complete culture medium. Untreated DCs were used as a positive 
control. Dendritic cells (4 × 105 cells/ml) primed with OVA (50 μg/ml) and matured in the 
presence of TNF-α (1,000 U/ml) were incubated with anti-ICAM-1 (1 μg/ml), anti-LFA-1 (5 
μg/ml), NPs (2.2 mg/ml), LABL peptide (0.095, 0.19 and 0.38 mM), LABL-NPs (1.1, 2.2 
and 4.4 mg/ml), cIBR peptide (0.012, 0.024 and 0.048 mM) or cIBR-NPs (1.1, 2.2 and 4.4 
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mg/ml) for 30 min at 37 °C. DCs were washed three times with PBS and incubated with T 
cells (2 × 106 cells/ml) for 2 hr at 37 °C. After incubation, DCs were washed three times 
with PBS and fixed with 4% paraformaldehyde. Cells were imaged using an Orca ER 
camera (Hamamatsu, Inc., Bridgewater, NJ) and imaged using Metamorph, version 6.2 
(Universal Imaging Corp., West Chester, PA). Dendritic cells and T-cells attached to 
dendritic cells were measured by using Image J software per condition from all images. The 
analysis was performed by using color segmentation (RGB channel separation), which was 
made binary and followed by measurement of the area of R and G channels. Similar 
threshold limiting was applied to all images and colors. The results were reported by the 
percent of ratio of R channel area (corresponds to T cells) to G channel area (corresponds to 
DC). The percentage of T cell-conjugates was calculated.
T cell proliferation assay
Primary T cells isolated from C57BL/6-TgN(OT-II.2a)-Rag1 mice were labeled with 
carboxyfluorescein succinimidyl ester (CFSE) (5 μM) for 10 min at 37 °C, 5% CO2 to 
observe the dye dilution by cell division. The staining was quenched by the addition of 5 
volumes of culture medium into T cells and incubated 10 min at 4°C. DCs (4 × 105 cells/ml) 
were matured in the presence of TNF-α (1,000 U/ml) and primed with OVA (50 μg/ml) for 
24 hrs in 24-well plate. DCs were treated with anti-ICAM-1 (1 μg/ml), anti-LFA-1 (5 μg/
ml), unconjugated NPs (2.2 mg/ml), LABL peptide (0.095, 0.19 and 0.38 mM), LABL-NPs 
(1.1, 2.2 and 4.4 mg/ml), cIBR peptide (0.012, 0.024 and 0.048 mM) or cIBR-NPs (1.1, 2.2 
and 4.4 mg/ml) for 30 min, at 37 °C, 5% CO2 and washed three times with PBS. T cells (2 × 
106 cells/ml) in serum free RPMI-1640, IL-2 and 1% penicillin-streptomycin were incubated 
with DCs 7 days at 37°C, 5% CO2. T cells collected after 24 hrs (1 day) and 168 hrs (7 days) 
were centrifuged at 16,089 g for 2 minutes and fixed with 4% paraformaldehyde. The CFSE 
dilution was measured by using FACScan flow cytometer. The percent of T cell 
proliferation was analyzed by calculating the percent of cells with diluted CFSE using 
FlowJo software.
Quantification of cytokines in cell culture supernatants by ELISA
DCs were matured in the presence of TNF-α (1,000 U/ml) and primed with OVA (50 μg/ml) 
for 24 hrs in 24-well plate. DCs were treated with anti-ICAM-1 (1 μg/ml), anti-LFA-1 (5 μg/
ml), unconjugated NPs (2.2 mg/ml), LABL peptide (0.095, 0.19 and 0.38 mM), LABL-NPs 
(1.1, 2.2 and 4.4 mg/ml), cIBR peptide (0.012, 0.024 and 0.048 mM) or cIBR-NPs (1.1, 2.2 
and 4.4 mg/ml) for 30 min, at 37 °C, 5% CO2 and washed three times with PBS. T cells (2 × 
106 cells/ml) in serum free RPMI-1640, IL-2 and 1% penicillin-streptomycin were incubated 
with DCs 7 days at 37°C, 5% CO2. Supernatants of cell cultures were collected for cytokine 
detection. Secreted TNF-α, IL-2, IL6 and IL-17 were measured by ELISA assay (Cytokine 
Core Lab, Baltimore, Maryland). ELISA was performed in Nunc Maxisorb ELISA strips 
freshly coated with capture antibody for 16 hours before the assay was performed. Detecting 
antibody and the streptavidin-peroxidase conjugate were added into standard, all samples 
Chittasupho et al. Page 12






















and controls. Premixed substrate solution (Neogen) was then added. The plate was read on a 
Molecular Divices ELISA plate reader. Curve fitting was selected among linear, quadratic 
and 4-point based on the best regression coefficient using the SoftPro software package.
Statistical analysis
Statistical evaluation of data was performed using an analysis of variance (one-way 
ANOVA). Newman-Keuls was used as a post-hoc test to assess the significance of 
differences. To compare the significance of the difference between the means of two groups, 
a t-test was performed; in all cases, a value of p < 0.05 was accepted as significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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T cell conjugation to DCs maybe blocked by the binding of cIBR-NP to LFA-1 or LABL-
NP to ICAM-1 on DCs.
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(A) ICAM-1 and LFA-1 expression on dendritic cells and on (B) T cells. OVA-primed DCs 
and T cells were incubated with anti-ICAM-1 and anti-LFA-1 for 45 min on ice. Cells were 
washed and analyzed by flow cytometry. ** indicates p<0.001 and * indicates p<0.05.
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Binding of NPs, LABL-NPs or cIBR-NPs to dendritic cells. NPs, LABL-NPs and cIBR-NPs 
were incubated with OVA-primed and TNF-α activated DCs for 15, 30, 45 or 60 min at 37 
°C and analyzed by flow cytometry. The interaction of cIBR-NPs with dendritic cells was 
significantly greater than LABL-NPs and untargeted NPs at all time points. The 
fluorescence of dendritic cells incubated with each of the NP types increased with time. * 
indicates p < 0.05, ** indicates p < 0.01 and *** indicates p < 0.001.
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(A) Fluorescent micrographs of DCs in medium (untreated), DCs incubated with untargeted 
NPs, DCs incubated with LABL-NPs and DCs incubated with cIBR-NPs for 40 min. 
Punctate fluorescence patterns suggested the accumulation of NPs with the cells (B) Mean 
fluorescent intensities of DCs incubated with NP, LABL-NP and cIBR-NP were quantified 
from micrographs using ImageJ software. DCs were stimulated by TNF-α and primed with 
OVA for 24 hrs prior to the study. DCs were then incubated with NPs, LABL-NPs and 
cIBR-NPs for 40 min at 37 °C. * indicates p < 0.001.
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Dendritic cell and T cell viability in the presence of (A) LABL-NPs or (B) cIBR-NPs. 
LABL-NPs and cIBR-NPs were minimally cytotoxic to DCs and T cells at the 
concentrations used for ensuing studies.
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(A) Blocking of DC-T cell conjugate formation. LABL-NPs and cIBR-NPs inhibited the 
binding of T cells to DCs to a much greater extent than free LABL and cIBR peptides. (B) 
Micrographs of T cells (red) binding DCs (green). LABL-NPs and cIBR-NPs exhibited 
greater inhibition oT cell conjugation to DCs than LABL peptides, anti-ICAM-1, anti-
LFA-1, NPs and untreated DCs. DCs were incubated with TNFα and primed with OVA for 
24 hrs prior to incubation with samples. DCs were washed and T cells were cocultured for 2 
hours and T cells and DCs were imaged and counted. *** indicates p<0.001.
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The proliferation of T cells after coculture with DCs treated with samples. The percent of T 
cells dividing after incubation for 24 hrs (1 day) and 168 hrs (7 days) was determined by 
flow cytometry. DCs incubated with TNFα and primed with OVA were incubated with 
samples for 30 min at 37 °C. After removing samples, OVA specific T cells were added and 
incubated with DCs for 7 days. cIBR-NPs and untargeted NPs stimulated the proliferation of 
OTII T cells but other samples did not significantly alter T cell proliferation. *** indicates 
p<0.001 and * indicates p<0.05.
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The production of cytokines in cocultures where DCs were pretreated with LABL-NPs, 
cIBR-NPs, untargeted NPs, LABL peptide or cIBR peptide. (A) All nanoparticles increased 
the secretion of TNF-α compared to untreated DCs. (B) LABL-NPs, cIBR-NPs, LABL and 
cIBR peptides decreased the amount of IL-6 detected in the coculture of DCs and T cells 
relative to untreated DCs. Untargeted NPs increased the level of IL-6 production in the 
coculture of DCs and T cells (C) Untargeted NPs induced the production of IL-17 from 
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activated OT-II T cells. LABL-NPs, cIBR-NPs, LABL and cIBR peptides did not stimulate 
the production of IL-17. *** indicates p<0.001 and ** indicates p<0.01.
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Table 1
Nanoparticle properties of specified formulations*
NP LABL-NP cIBR-NP
Effective diameter (nm) 154.6 ± 10.0 172.6 ± 2.5 171.9 ± 4.3
Polydispersity 0.026 ± 0.030 0.070 ± 0.039 0.055 ± 0.005
Zeta potential (mV) −21.4 ± 0.4 −34.7± 2.0 −13.9 ± 0.8
*
Values are representative of three experiments (mean ± S.D.).
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Table 2







LABL-NP 172.6 25.9 265.5 ± 78.5
cIBR-NP 171.9 26.1 39.5 ± 3.0
*
Values are representative of three experiments (mean ± S.D.)
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